Details

Autor(en) / Beteiligte

• Torrey, E. Fuller

Titel

Did the human genome project affect research on Schizophrenia?

Ist Teil von

• Psychiatry research, 2024-03, Vol.333, p.115691-115691, Article 115691

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Schizophrenia, thought by many to be a genetic disorder, was specifically targeted for study by the Human Genome Project.•Extensive genetic studies have identified almost 300 risk genes but no causal gene.•NIMH invested extensive resources in this research with little to show for it and at the expense of alternative research projects.•Since schizophrenia does not appear to be a genetic disorder, NIMH's research portfolio should be reviewed. The Human Genome Project was undertaken primarily to discover genetic causes and better treatments for human diseases. Schizophrenia was targeted since three of the project`s principal architects had a personal interest and also because, based on family, adoption, and twin studies, schizophrenia was widely believed to be a genetic disorder. Extensive studies using linkage analysis, candidate genes, genome wide association studies [GWAS], copy number variants, exome sequencing and other approaches have failed to identify causal genes. Instead, they identified almost 300 single nucleotide polymorphisms [SNPs] associated with altered risks of developing schizophrenia as well as some rare variants associated with increased risk in a small number of individuals. Risk genes play a role in the clinical expression of most diseases but do not cause the disease in the absence of other factors. Increasingly, observers question whether schizophrenia is strictly a genetic disorder. Beginning in 1996 NIMH began shifting its research resources from clinical studies to basic research based on the promise of the Human Genome Project. Consequently, three decades later NIMH's genetics investment has yielded almost nothing clinically useful for individuals currently affected. It is time to review NIMH`s schizophrenia research portfolio.